ProCE Banner Activity

LEAP-002: Placebo-Controlled Phase III Trial of Lenvatinib ± Pembrolizumab as First-line Therapy for Advanced HCC

Slideset Download
Conference Coverage
Primary results from the phase III LEAP-002 study showed that first-line treatment with lenvatinib plus pembrolizumab was not superior to lenvatinib plus placebo in patients with advanced hepatocellular carcinoma.

Released: September 19, 2022

Expiration: September 18, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.